Fig. 5
Survival and antitumor effects of MC180295, DAC, or their combination, with/without CD8 + T cells. A 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Mouse survival in days. B Survival of B6 mice, after CD8 depletion, using an anti-CD8 antibody. 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. C Antitumor effects of MC180295 with and without CD8 depletion, using an anti-CD8 antibody. B6 mice were inoculated (s.c.) with 5 × 105 CT26.CL25 cells. Eight days later, when tumors were palpable, 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Tumor sizes were measured using a caliper and calculated over vehicle. D Antitumor effects of DAC, with and without CD8 depletion, using an anti-CD8 antibody. B6 mice were inoculated (s.c.) with 5 × 105 CT26.CL25 cells. Eight days later, when tumors were palpable, 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Tumor sizes were measured using a caliper and calculated over vehicle. E Antitumor effects of DAC + MC180295, with and without CD8 depletion, using an anti-CD8 antibody. B6 mice were inoculated (s.c.) with 5 × 105 CT26.CL25 cells. Eight days later, when tumors were palpable, 20 mg/kg MC180295 was administered (i.p.) q.o.d. 0.5 mg/kg DAC was administered (i.p.) daily. Tumor sizes were measured using a caliper and calculated over vehicle. Significances were calculated using log-rank (Mantel-Cox) or Student's T tests. Data shown as means ± SEMs